Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Steatotic liver disease risk scores compared for predicting cirrhosis (opens in a new tab)

medicalxpress.com · 2026-09-25

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 6 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All six claims match what the study reports.

  • 6 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6SupportedFor patients with steatotic liver disease, the steatosis-associated fibrosis estimator (SAFE) score demonstrated the greatest net benefit for predicting cirrhosis.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that SAFE had the greatest decision-curve net benefit for predicting 10-year incident cirrhosis. The claim is accurate when understood in the study population of noncirrhotic, imaging-confirmed SLD patients in the VA system, which the story mentions elsewhere.

1

Study evidence

The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.

“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
Claim 2 of 6SupportedCatherine Mezzacappa and colleagues compared the clinical utility of nine SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic SLD.View evidenceHide evidence

Why this verdict

The profile supports that the study compared the clinical utility of nine SLD risk scores for predicting incident cirrhosis and HCC within 10 years among noncirrhotic adults with imaging-confirmed SLD. Authorship is not encoded in the supplied profile, but the scientific content of the claim is supported.

1

Study evidence

The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.

“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
2

Study evidence

Low absolute incidence of HCC: 2978 of 853,131 patients (0.35%) developed HCC within 10 years.0.35% 10-year cumulative incidence (2978/853,131)

“First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry.”
Claim 3 of 6SupportedThe cohort study used data from adults with imaging-confirmed SLD in the national U.S. Veterans Affairs health system, including 853,131 patients.View evidenceHide evidence

As stated853,131 patients

Why this verdict

The profile states that this was a cohort study using national US Veterans Affairs data in adults with imaging-confirmed SLD and reports a cohort size of 853,131 patients.

1

Study evidence

The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.

“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
2

Study evidence

Low absolute incidence of HCC: 2978 of 853,131 patients (0.35%) developed HCC within 10 years.0.35% 10-year cumulative incidence (2978/853,131)

“First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry.”
Claim 4 of 6SupportedThe analysis found that 3.96% developed cirrhosis and 0.35% developed hepatocellular carcinoma within 10 years.View evidenceHide evidence

As statedwithin 10 years: 3.96% cirrhosis; 0.35% HCC

Why this verdict

The profile reports that within 10 years, 33,794 of 853,131 patients developed cirrhosis, or 3.96%, and 2,978 developed HCC, or 0.35%.

1

Study evidence

The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.

“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
2

Study evidence

Low absolute incidence of HCC: 2978 of 853,131 patients (0.35%) developed HCC within 10 years.0.35% 10-year cumulative incidence (2978/853,131)

“First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry.”
Claim 5 of 6SupportedFIB-4, the aspartate aminotransferase-to-platelet ratio index, and SAFE showed the greatest discrimination of cirrhosis risk, while SAFE, Tate, and FIB-4 showed the greatest discrimination of HCC risk.View evidenceHide evidence

Why this verdict

The profile reports that FIB-4, APRI, and SAFE had the greatest discrimination for cirrhosis risk, while SAFE, Tate, and FIB-4 had the greatest discrimination for HCC risk. This claim is appropriately framed as discrimination rather than clinical utility.

1

Study evidence

The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.

“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
2

Study evidence

Low absolute incidence of HCC: 2978 of 853,131 patients (0.35%) developed HCC within 10 years.0.35% 10-year cumulative incidence (2978/853,131)

“First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry.”
Claim 6 of 6SupportedA score of 29.5 on SAFE corresponded to a 10-year cirrhosis risk of 2.5% and a net benefit of 0.019; at a 0.25% 10-year HCC risk threshold, SAFE had a net benefit of 0.0016.View evidenceHide evidence

As stated2.5% 10-year cirrhosis risk; net benefit 0.019; 0.0016 at 0.25% 10-year HCC risk

Why this verdict

The profile supports both numeric examples: SAFE score 29.5 corresponded to 2.5% 10-year cirrhosis risk and net benefit 0.019, and at a 0.25% 10-year HCC risk threshold, SAFE had net benefit 0.0016.

1

Study evidence

The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.

“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
2

Study evidence

Low absolute incidence of HCC: 2978 of 853,131 patients (0.35%) developed HCC within 10 years.0.35% 10-year cumulative incidence (2978/853,131)

“First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • HCC clinical-utility conclusion: despite the HCC discrimination rankings, the evaluated scores showed minimal clinical utility for informing HCC screening decisions in noncirrhotic SLD.

    The story reports the best HCC discrimination scores and one small SAFE net-benefit value, but it does not state the paper's interpretation that HCC screening utility was minimal. This omission could make the HCC findings sound more clinically useful than the paper concludes.

    From Retrospective cohort study

  • Generalizability limitation: the VA cohort was predominantly male, which may limit applicability to broader, more sex-balanced populations.

    The story notes the VA setting but does not mention the strongly male composition of the cohort, which is a material generalizability limitation in the profile.

    From Retrospective cohort from administrative/clinical VA data; Retrospective cohort study

  • Outcome ascertainment limitation: cirrhosis and HCC outcomes were identified using VA/Medicare diagnosis codes and registry data, creating potential for misclassification.

    The story does not mention coding- or registry-based outcome ascertainment or potential misclassification.

    From Retrospective cohort from administrative/clinical VA data; Retrospective cohort study

  • Retrospective observational secondary-data design limitation: residual confounding and selection bias may affect interpretation.

    The story describes the work as a cohort study but does not mention that it was retrospective or discuss residual confounding or selection biases inherent to the design.

    From Retrospective cohort from administrative/clinical VA data; Retrospective cohort study

4 things the story did carry across
  • Study design and population: retrospective cohort of noncirrhotic adults with imaging-confirmed SLD in the national US Veterans Affairs system, with nine risk scores calculated at first steatosis-confirming imaging.
  • Primary cirrhosis clinical-utility finding: SAFE had the greatest decision-curve net benefit for predicting 10-year incident cirrhosis and may inform repeat cirrhosis screening decisions.
  • Discrimination rankings: FIB-4, APRI, and SAFE performed best for cirrhosis discrimination; SAFE, Tate, and FIB-4 performed best for HCC discrimination.
  • Threshold dependence of net benefit and clinical utility: decision-curve conclusions depend on chosen risk thresholds and clinical context.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCompare the clinical utility of 9 steatotic liver disease (SLD) risk scores for predicting incident cirrhosis within 10 years among noncirrhotic adults with imaging-confirmed SLD in the US Veterans Affairs system, including discrimination and decision-curve net benefit to inform cirrhosis surveillance decisions.Retrospective cohort from administrative/clinical VA dataExpand

In plain English

Retrospective cohort study of 853,131 US Veterans with imaging-confirmed steatotic liver disease (2008–2020) comparing 9 clinical risk scores (calculated at first steatosis imaging) for prediction of incident cirrhosis and hepatocellular carcinoma (HCC) within 10 years using Cox models and decision-curve (net benefit) analysis. SAFE had the greatest net benefit for predicting 10-year cirrhosis and, together with FIB-4 and APRI, among the best discrimination for cirrhosis; clinical utility of scores for HCC screening was minimal.

Key findings

  • The SAFE score provided the greatest decision-curve net benefit for predicting 10-year incident cirrhosis among noncirrhotic patients with imaging-confirmed SLD.net benefit = 0.019 at SAFE score = 29.5 (corresponding 10-year cirrhosis risk = 2.5%); equivalent to 1.9 additional true positives per 100 individuals labeled at-risk.
  • FIB-4, APRI, and SAFE demonstrated the greatest discrimination for cirrhosis risk; SAFE, Tate, and FIB-4 demonstrated the greatest discrimination for HCC risk among evaluated scores.
“This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD”
What this piece can’t prove
  • Predominantly male VA population (92.7% male) may limit generalizability to broader, more gender-balanced populations.
  • Outcome ascertainment relied on VA and Medicare diagnostic codes and registry data, which can introduce misclassification.
  • Retrospective observational design; potential for residual confounding and selection biases inherent to secondary-data analyses.
  • Abstract provides limited detail on full set of discrimination metrics and calibration across scores; thresholds and net-benefit interpretation depend on clinical context and chosen risk thresholds.
2secondary dataCompare the clinical utility of the same 9 SLD risk scores for predicting incident hepatocellular carcinoma (HCC) within 10 years in the same noncirrhotic SLD cohort, including discrimination and decision-curve net benefit to inform HCC screening decisions.Retrospective cohort studyExpand

In plain English

In a retrospective VA cohort of adults with imaging-confirmed noncirrhotic steatotic liver disease (2008–2020), nine preexisting clinical risk scores computed at index imaging were compared for predicting incident hepatocellular carcinoma (HCC) within 10 years using Cox models for time-dependent risk and decision-curve analysis (net benefit). SAFE, Tate, and FIB-4 showed the highest discrimination for HCC; however, absolute HCC incidence was low (2978 events, 0.35% over 10 years) and clinical utility was minimal — e.g., SAFE net benefit 0.0016 at a 0.25% 10-year risk threshold (≈1.6 additional true positives per 1000 individuals). The authors conclude these risk scores have minimal utility to inform HCC screening decisions in patients with noncirrhotic SLD.

Key findings

  • Low absolute incidence of HCC: 2978 of 853,131 patients (0.35%) developed HCC within 10 years.0.35% 10-year cumulative incidence (2978/853,131)
  • Relative discrimination: SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination for 10-year HCC risk among the nine evaluated scores.
“First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry.”
What this piece can’t prove
  • Study population is from the US Veterans Affairs system and is predominantly male (92.7%), which limits generalizability to broader, more sex-balanced populations.
  • HCC incidence over 10 years was low (0.35%), which constrains statistical power and yields small absolute net benefits for screening decisions.
  • Outcome ascertainment relied on administrative diagnosis codes plus cancer registry linkage; potential for misclassification or incomplete capture exists.
  • Abstract does not report numeric discrimination metrics or calibration details for HCC risk scores, limiting assessment of magnitude of performance differences.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 28 candidate papers

And 22 more candidates considered.